Home Alzheimer’s Disease FDA Approves Multi-Dose Vial of Trastuzumab Biosimilar

FDA Approves Multi-Dose Vial of Trastuzumab Biosimilar

The FDA has approved a 420 mg multi-dose vial of trastuzumab-dttb (Ontruzant), a biosimilar referencing trastuzumab (Herceptin), according to Samsung Bioepis, the agent’s developer.1

Trastuzumab-dttb was already approved as a 150 mg single-dose vial by the FDA in January 2019 across all eligible indications, including adjuvant treatment of HER2-overexpressing breast cancer, metastatic breast cancer, and metastatic gastric cancer or gastroesophageal junction adenocarcinoma in patients who have not received prior treatment for metastatic disease.

The European Commission approved the biosimilar in November 2017.

The biosimilar is indicated for adjuvant treatment of HER2-overexpressing node-positive or node-negative (ER/PR-negative or with one high-risk feature) breast cancer, including:

  • As part of a treatment regimen containing doxorubicin (Lipodox), cyclophosphamide, and either…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

please help us fundraise (501c3 non-profit) : braincancer

I work with OurBrainBank, a start-up non-profit dedicated to moving glioblastoma from terminal to treatable, powered by patients.We're a registered 501c3 non-profit in the...

Cancer and Mental Health Re-post : braincancer

Hello!I would like to thank everyone who participated in my survey these past few months! I received a tremendous response and I truly, truly...

I put my feelings in music. : braincancer

Song LinkHi amigos. My 2year old son has been battling cancer for nearly 6 months and this song is just a expression of my...

Podcast Episode Interviewing Brain Cancer Fighter & Survivor : braincancer

Hi all, we have a podcast called Making Headway that is meant as a support for brain injury survivors. My co-host, Eryn, and I...

Recent Comments